Analyst Price Targets — SGMO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 31, 2024 3:55 pm | Maury Raycroft | Jefferies | $3.00 | $1.02 | TheFly | Sangamo price target lowered to $3 from $7 at Jefferies |
| December 31, 2024 10:10 am | Yanan Zhu | Wells Fargo | $2.00 | $1.02 | TheFly | Sangamo price target lowered to $2 from $3 at Wells Fargo |
| June 13, 2022 7:25 am | Andreas Argyrides | Wedbush | $5.00 | $3.76 | TheFly | Sangamo assumed with a Neutral at Wedbush |
| April 5, 2022 12:00 am | Nicole Germino | Truist Financial | $19.00 | $6.15 | Pulse 2.0 | Sangamo BioSciences (SGMO) Stock: Why The Price Increased |
Latest News for SGMO
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in study, which U.S. Food and Drug Administration (FDA) reiterated in October may serve as primary basis of approval under Accelerated Approval pathway Rolling submission of Biologics License Agreement…
Sangamo Therapeutics will release Q4 earnings on March 30. Analysts predict a quarterly loss of 5 cents per share and revenue of $40.25 million.
RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026.
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SGMO.
U.S. House Trading
No House trades found for SGMO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.